Antisense and RNAi Therapeutics Market Report 2031 | The Insight Partners
The Antisense and RNAi Therapeutics Market is expected to register a CAGR of 7.50% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report presents an analysis based on by type (rna interference, antisense rna). The report is segmented by route of administration (pulmonary delivery, intravenous injections, intra-dermal, intraperitoneal, topical, others). The report further provides analysis based on application (infectious diseases, cardiovascular diseases, cancer, neurological disorders, others). The global analysis is further broken-down at regional level and major countries. The market size and forecast at global, regional, and country levels for all the key market segments are covered under the scope. The report offers the value in USD for the above analysis and segments. The report provides key statistics on the market status of the key market players and offers market trends and opportunities.
Purpose of the ReportThe report Antisense and RNAi Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Antisense and RNAi Therapeutics Market Segmentation
Type- RNA Interference
- Antisense RNA
- Pulmonary Delivery
- Intravenous Injections
- Intra-Dermal
- Intraperitoneal
- Topical
- Others
- Infectious Diseases
- Cardiovascular Diseases
- Cancer
- Neurological Disorders
- Others
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Strategic Insights
Antisense and RNAi Therapeutics Market Growth Drivers- Increased diseases genetic incidence: The increasing incidence of genetic disorders, including rare diseases, was a major driver in the antisense and RNAi therapeutics market. Specific mutations are targeted by the therapies for an individualized treatment option for conditions such as Duchenne muscular dystrophy and cystic fibrosis; therefore, increasing gene-silencing technologies' demand.
- Advancements in RNA Technology: Continuous advancements ongoing in RNA-based technology, improved delivery systems, and enhanced stability of RNA molecules are expected to boost the antisense and RNAi therapeutics market. The precision and efficacy improvements would render these therapies much more viable and effective to develop in clinical application.
- Increasing Investment in Gene Therapies:Increased investments in gene therapies are leading the antisense and RNAi therapeutic market to flourish. Pharma companies are putting in a lot of money into developing RNA-targeting drugs while at the same time governments and private investors are funding their research, paving way for fast progress and new RNA therapies to be available for diseases.
- Approach of Personalized Medicine: The personalized RNA therapy is a novel type of treatment that is formed according to one's individual genetic makeup. Such forms of treatment render the ability to develop a treatment for a specific genetic mutation that increases effectiveness, decreases side effects, and augments patient outcomes. Thus, it shapes the future of RNA-based therapeutic innovations and establishes a more precise mode for treating disease.
- Innovate RNA Delivery Systems: The future RNA based therapies lie in the development of novel RNA delivery technologies such as nanoparticles based carriers, lipid nanoparticles, and several emerging delivery systems to challenge the limitations of RNA stability and efficiency of gene silencing, which in turn would focus the market towards practicality and scalability.
- Combination Therapies with RNAi: There is a growing trend in the direction of combination of RNAi therapeutics with other therapeutic modalities, such as immunotherapies or small molecules. These treatments should improve therapeutic outcomes because they target more than one pathway at the same time, thus holding promise for increasing efficacy and/ or for widening the indications and applications for which RNA therapies offer therapy in oncology, cardiovascular, and genetic diseases.
- Increased Attention towards Rare Diseases: It is increasing in focus on orphan and other rare diseases with the promise of RNA therapeutics to treat such diseases. As presently, many rare genetic disorders do not have effective treatments, an antisense and RNAi approach is a novel way to solve this demand-supply gap and drive research and development in these niche areas. Combination therapy with such innovative approaches or co-developing gene editing can help broaden the offering and accelerate bringing new intervention to life for complex diseases.
- Developing Over-the-Counter RNAi Therapies:It is a good business opportunity to develop RNAi therapies for over-the-counter treatments, especially for dermatological conditions that do not require clinical treatment or chronic diseases. Such therapies would go a long way in encouraging a movement towards self-care and individualization of medicine, with self-care increasingly becoming a viable mode for administering RNAi products-the latter being less than, if not now already completely out of, the parameters of healthcare.
- Focus on Cancer Therapies:Cancer is a major opportunity for the antisense and RNAi therapeutics space. The targeting of specific oncogenes involved in tumorigenesis can also lead to personalized treatment with less adverse effects. With such an emerging emphasis on precision oncology, the expansion of RNA therapies into such cancer treatment works ideally, making this an attractive opportunity.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antisense and RNAi Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Antisense and RNAi Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORKHave a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Abbott, biomeruix SA, Quest Diagnostics, Biomerica, Danaher corporation, Trinity biotech, BD, Bio-rad Laboratories
Asia Pacific region dominated the antisense and RNAi therapeutics market in 2023
The major driving factors of antisense and RNAi therapeutics market are:
1. Increased cases of TB worldwide
2. Advances in Diagnostic Technologies
3. Igovernment initiatives and funding
North America region dominated the antisense and RNAi therapeutics market in 2023
The Antisense and RNAi Therapeutics Market is estimated to witness a CAGR of 7.50% from 2023 to 2031
Advancing trend in POC testing
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antisense And RNAi Therapeutics Market - By Type
1.3.2 Antisense And RNAi Therapeutics Market - By Route of Administration
1.3.3 Antisense And RNAi Therapeutics Market - By Application
1.3.4 Antisense And RNAi Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTISENSE AND RNAI THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTISENSE AND RNAI THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTISENSE AND RNAI THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTISENSE AND RNAI THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. ANTISENSE AND RNAI THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ANTISENSE AND RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. RNA INTERFERENCE
7.3.1. Overview
7.3.2. RNA Interference Market Forecast and Analysis
7.4. ANTISENSE RNA
7.4.1. Overview
7.4.2. Antisense RNA Market Forecast and Analysis
8. ANTISENSE AND RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. PULMONARY DELIVERY
8.3.1. Overview
8.3.2. Pulmonary Delivery Market Forecast and Analysis
8.4. INTRAVENOUS INJECTIONS
8.4.1. Overview
8.4.2. Intravenous Injections Market Forecast and Analysis
8.5. INTRA-DERMAL
8.5.1. Overview
8.5.2. Intra-Dermal Market Forecast and Analysis
8.6. INTRAPERITONEAL
8.6.1. Overview
8.6.2. Intraperitoneal Market Forecast and Analysis
8.7. TOPICAL
8.7.1. Overview
8.7.2. Topical Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ANTISENSE AND RNAI THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. INFECTIOUS DISEASES
9.3.1. Overview
9.3.2. Infectious Diseases Market Forecast and Analysis
9.4. CARDIOVASCULAR DISEASES
9.4.1. Overview
9.4.2. Cardiovascular Diseases Market Forecast and Analysis
9.5. CANCER
9.5.1. Overview
9.5.2. Cancer Market Forecast and Analysis
9.6. NEUROLOGICAL DISORDERS
9.6.1. Overview
9.6.2. Neurological Disorders Market Forecast and Analysis
9.7. OTHERS.
9.7.1. Overview
9.7.2. Others. Market Forecast and Analysis
10. ANTISENSE AND RNAI THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Antisense And RNAi Therapeutics Market Overview
10.1.2 North America Antisense And RNAi Therapeutics Market Forecasts and Analysis
10.1.3 North America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Type
10.1.4 North America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Application
10.1.6 North America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 Canada Antisense And RNAi Therapeutics Market
10.1.6.1.1 Canada Antisense And RNAi Therapeutics Market by Type
10.1.6.1.2 Canada Antisense And RNAi Therapeutics Market by Route of Administration
10.1.6.1.3 Canada Antisense And RNAi Therapeutics Market by Application
10.1.6.2 Mexico Antisense And RNAi Therapeutics Market
10.1.6.2.1 Mexico Antisense And RNAi Therapeutics Market by Type
10.1.6.2.2 Mexico Antisense And RNAi Therapeutics Market by Route of Administration
10.1.6.2.3 Mexico Antisense And RNAi Therapeutics Market by Application
10.1.6.3 US Antisense And RNAi Therapeutics Market
10.1.6.3.1 US Antisense And RNAi Therapeutics Market by Type
10.1.6.3.2 US Antisense And RNAi Therapeutics Market by Route of Administration
10.1.6.3.3 US Antisense And RNAi Therapeutics Market by Application
10.2. EUROPE
10.2.1 Europe Antisense And RNAi Therapeutics Market Overview
10.2.2 Europe Antisense And RNAi Therapeutics Market Forecasts and Analysis
10.2.3 Europe Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Type
10.2.4 Europe Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Application
10.2.6 Europe Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Antisense And RNAi Therapeutics Market
10.2.6.1.1 Germany Antisense And RNAi Therapeutics Market by Type
10.2.6.1.2 Germany Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.1.3 Germany Antisense And RNAi Therapeutics Market by Application
10.2.6.2 France Antisense And RNAi Therapeutics Market
10.2.6.2.1 France Antisense And RNAi Therapeutics Market by Type
10.2.6.2.2 France Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.2.3 France Antisense And RNAi Therapeutics Market by Application
10.2.6.3 Italy Antisense And RNAi Therapeutics Market
10.2.6.3.1 Italy Antisense And RNAi Therapeutics Market by Type
10.2.6.3.2 Italy Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.3.3 Italy Antisense And RNAi Therapeutics Market by Application
10.2.6.4 Spain Antisense And RNAi Therapeutics Market
10.2.6.4.1 Spain Antisense And RNAi Therapeutics Market by Type
10.2.6.4.2 Spain Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.4.3 Spain Antisense And RNAi Therapeutics Market by Application
10.2.6.5 United Kingdom Antisense And RNAi Therapeutics Market
10.2.6.5.1 United Kingdom Antisense And RNAi Therapeutics Market by Type
10.2.6.5.2 United Kingdom Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.5.3 United Kingdom Antisense And RNAi Therapeutics Market by Application
10.2.6.6 Rest of Europe Antisense And RNAi Therapeutics Market
10.2.6.6.1 Rest of Europe Antisense And RNAi Therapeutics Market by Type
10.2.6.6.2 Rest of Europe Antisense And RNAi Therapeutics Market by Route of Administration
10.2.6.6.3 Rest of Europe Antisense And RNAi Therapeutics Market by Application
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Antisense And RNAi Therapeutics Market Overview
10.3.2 Asia-Pacific Antisense And RNAi Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Application
10.3.6 Asia-Pacific Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Antisense And RNAi Therapeutics Market
10.3.6.1.1 Australia Antisense And RNAi Therapeutics Market by Type
10.3.6.1.2 Australia Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.1.3 Australia Antisense And RNAi Therapeutics Market by Application
10.3.6.2 China Antisense And RNAi Therapeutics Market
10.3.6.2.1 China Antisense And RNAi Therapeutics Market by Type
10.3.6.2.2 China Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.2.3 China Antisense And RNAi Therapeutics Market by Application
10.3.6.3 India Antisense And RNAi Therapeutics Market
10.3.6.3.1 India Antisense And RNAi Therapeutics Market by Type
10.3.6.3.2 India Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.3.3 India Antisense And RNAi Therapeutics Market by Application
10.3.6.4 Japan Antisense And RNAi Therapeutics Market
10.3.6.4.1 Japan Antisense And RNAi Therapeutics Market by Type
10.3.6.4.2 Japan Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.4.3 Japan Antisense And RNAi Therapeutics Market by Application
10.3.6.5 South Korea Antisense And RNAi Therapeutics Market
10.3.6.5.1 South Korea Antisense And RNAi Therapeutics Market by Type
10.3.6.5.2 South Korea Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.5.3 South Korea Antisense And RNAi Therapeutics Market by Application
10.3.6.6 Rest of Asia-Pacific Antisense And RNAi Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Antisense And RNAi Therapeutics Market by Type
10.3.6.6.2 Rest of Asia-Pacific Antisense And RNAi Therapeutics Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Antisense And RNAi Therapeutics Market by Application
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Antisense And RNAi Therapeutics Market Overview
10.4.2 Middle East and Africa Antisense And RNAi Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Application
10.4.6 Middle East and Africa Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Antisense And RNAi Therapeutics Market
10.4.6.1.1 South Africa Antisense And RNAi Therapeutics Market by Type
10.4.6.1.2 South Africa Antisense And RNAi Therapeutics Market by Route of Administration
10.4.6.1.3 South Africa Antisense And RNAi Therapeutics Market by Application
10.4.6.2 Saudi Arabia Antisense And RNAi Therapeutics Market
10.4.6.2.1 Saudi Arabia Antisense And RNAi Therapeutics Market by Type
10.4.6.2.2 Saudi Arabia Antisense And RNAi Therapeutics Market by Route of Administration
10.4.6.2.3 Saudi Arabia Antisense And RNAi Therapeutics Market by Application
10.4.6.3 U.A.E Antisense And RNAi Therapeutics Market
10.4.6.3.1 U.A.E Antisense And RNAi Therapeutics Market by Type
10.4.6.3.2 U.A.E Antisense And RNAi Therapeutics Market by Route of Administration
10.4.6.3.3 U.A.E Antisense And RNAi Therapeutics Market by Application
10.4.6.4 Rest of Middle East and Africa Antisense And RNAi Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Antisense And RNAi Therapeutics Market by Type
10.4.6.4.2 Rest of Middle East and Africa Antisense And RNAi Therapeutics Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Antisense And RNAi Therapeutics Market by Application
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Antisense And RNAi Therapeutics Market Overview
10.5.2 South and Central America Antisense And RNAi Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Type
10.5.4 South and Central America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Application
10.5.6 South and Central America Antisense And RNAi Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Antisense And RNAi Therapeutics Market
10.5.6.1.1 Brazil Antisense And RNAi Therapeutics Market by Type
10.5.6.1.2 Brazil Antisense And RNAi Therapeutics Market by Route of Administration
10.5.6.1.3 Brazil Antisense And RNAi Therapeutics Market by Application
10.5.6.2 Argentina Antisense And RNAi Therapeutics Market
10.5.6.2.1 Argentina Antisense And RNAi Therapeutics Market by Type
10.5.6.2.2 Argentina Antisense And RNAi Therapeutics Market by Route of Administration
10.5.6.2.3 Argentina Antisense And RNAi Therapeutics Market by Application
10.5.6.3 Rest of South and Central America Antisense And RNAi Therapeutics Market
10.5.6.3.1 Rest of South and Central America Antisense And RNAi Therapeutics Market by Type
10.5.6.3.2 Rest of South and Central America Antisense And RNAi Therapeutics Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Antisense And RNAi Therapeutics Market by Application
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ANTISENSE AND RNAI THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. ALNYLAM PHARMACEUTICALS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BENITEC BIOPHARMA LTD.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. QUARK PHARMACEUTICALS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. IONIS PHARMACEUTICALS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTELLAS PHARMA INC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MARINA BIOSCIENCES
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SANOFI S
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. DICERNA PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. TEKMIRA PHARMACEUTICALS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MERCK
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Alnylam Pharmaceuticals
2. Benitec Biopharma Ltd.
3. Quark Pharmaceuticals
4. Ionis Pharmaceuticals
5. Astellas Pharma Inc
6. Marina Biosciences
7. Sanofi S
8. Dicerna Pharmaceuticals
9. Tekmira Pharmaceuticals
10. Merck
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.